Vertex builds in gene editing yet again, with $1.2bn Arbor dealVertex Pharma has ramped up its involvement in gene-editing medicines for the third time in a matter of Share XVertex builds in gene editing yet again, with $1.2bn Arbor dealhttps://pharmaphorum.com/news/vertex-builds-in-gene-editing-yet-again-with-1-2bn-arbor-deal/
Vertex eyes controllable genetic drugs with $1.3bn Obsidian allianceVertex Pharma has ramped up its involvement in gene-editing medicines for the second time in a week, paying Share XVertex eyes controllable genetic drugs with $1.3bn Obsidian alliancehttps://pharmaphorum.com/news/vertex-eyes-controllable-genetic-drugs-with-1-3bn-obsidian-alliance/
FDA fast tracks type 1 diabetes cell therapy from VertexVertex Pharma has made its name with treatment for cystic fibrosis, but has big plans in cell and Share XFDA fast tracks type 1 diabetes cell therapy from Vertexhttps://pharmaphorum.com/news/vertex-claims-fda-fast-track-status-for-diabetes-cell-therapy/
ASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordersA gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta Share XASH: CRISPR, Vertex’ CTX001 hits the mark in red cell disordershttps://pharmaphorum.com/news/ash-crispr-vertex-ctx001-hits-the-mark-in-red-cell-disorders/
Vertex gets EU okay to treat younger cystic fibrosis patientsA new EMA approval has expanded the use of Vertex Pharma’s cystic fibrosis therapy Symkevi to children as Share XVertex gets EU okay to treat younger cystic fibrosis patientshttps://pharmaphorum.com/news/vertex-gets-eu-okay-to-treat-younger-cystic-fibrosis-patients/
Vertex Pharma’s vision for reimbursement innovationAs regional vice president for Northern Europe & Australia, Simon Lem led the digital launch of Vertex Pharma’s Share XVertex Pharma’s vision for reimbursement innovationhttps://pharmaphorum.com/views-analysis-market-access/vertex-pharmas-vision-for-reimbursement-innovation/
Moderna broadens R&D scope with Vertex, Chiesi alliancesAll eyes may be on Moderna’s COVID-19 vaccine at the moment, but the US biotech hasn’t been idle Share XModerna broadens R&D scope with Vertex, Chiesi allianceshttps://pharmaphorum.com/news/moderna-broadens-rd-scope-with-vertex-chiesi-alliances/
Celebrations as NHS England agrees deal for Vertex’ cystic fibrosis tripleNHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after Share XCelebrations as NHS England agrees deal for Vertex’ cystic fibrosis triplehttps://pharmaphorum.com/news/celebrations-as-nhs-england-agrees-deal-for-vertex-cystic-fibrosis-triple/
As CHMP backs Vertex’ CF triple, campaigners plead for speedy UK dealCystic fibrosis patient groups in the UK are celebrating a recommendation by the EMA’s human medicines committee to Share XAs CHMP backs Vertex’ CF triple, campaigners plead for speedy UK dealhttps://pharmaphorum.com/news/as-chmp-backs-vertex-cf-triple-campaigners-plead-for-speedy-uk-deal/
